Zydus Cadila files IND application for diabetes treatment

By Elaine Rigoli

Tampa, Fla., March 27 - Cadila Healthcare Ltd. has filed an Investigational New Drug application for the New Molecular Entity (NME) - ZYH2 with the Drug Controller General of India.

The novel agent for treating diabetes has been designed and developed by Zydus Research Center, the research wing of the company.

ZYH2 has displayed a unique profile in preclinical studies, including the potential to improve insulin resistance and lower blood glucose in diabetic conditions without causing hypoglycemia and works favorably to lower elevated lipid levels, according to a news release.

The World Health Organization predicts the number of diabetics in India will increase to 40 million by 2010 and 74 million by 2025.

With this filing, Zydus Cadila has filed three INDs for ZYH1, ZYH and ZYH2.

The NME - ZYH1 has now entered phase 2 clinical trials, the release said.

Zydus Cadila, an international health care solutions company, has headquarters in Ahmedabad, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.